Antitumor Efficacy of Mammalian Target of Rapamycin Inhibitor Therapy in Liver Transplant Recipients With Oncological Disease: A Case-Control Study

Surprising differences in survival and tumor recurrence rates were observed among the mTORi-treated group compared with controls. Switching from CNI to mTORi immunosuppressant therapy appeared to be safe. It seems to be reasonable to employ this strategy in liver transplant patients with primary hepatic or “de novo” neoplasms.